A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

This trial is testing a drug combination — fruquintinib (a targeted therapy) plus FOLFIRI (a standard chemotherapy regimen) — as a second-line treatment for people with metastatic colorectal cancer (cancer that has spread from the colon or rectum to other organs). **You may be eligible if...** - You are 18 or older - You have metastatic colorectal cancer confirmed by biopsy - You previously received a standard first-line chemotherapy regimen containing oxaliplatin and bevacizumab, and your cancer has since progressed - You have at least one measurable tumor lesion on a scan **You may NOT be eligible if...** - Your colorectal cancer is microsatellite instability-high (MSI-H) or has a BRAF V600 mutation - You have already received more than one prior treatment for metastatic disease - You have significant heart disease or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.